Med. praxi. 2024;21(2):85-87 | DOI: 10.36290/med.2024.009

Lean obesity - a hidden health risk

Mgr. Erika Čermáková, Mgr. Martin Forejt, Ph.D.
Ústav veřejného zdraví, Lékařská fakulta, Masarykova univerzita, Brno

The phenotype of normal weight obesity (NWO) is a serious health risk but is often ignored in the diagnosis of obesity. The WHO defines obesity as an excessive or abnormal accumulation of adipose tissue, but the current diagnosis of adiposity is most often based on BMI values. Some individuals may have an increased amount of adipose tissue even though their BMI indicates that their weight is normal. This negative state is associated with an increased risk of cardiometabolic dysregulation and the subsequent development of chronic non-infectious diseases of the mass type. The global prevalence is only estimated to be around 4.5 - 22 % in the adult population due to the disunited definition of NWO. Current knowledge about the etiology of the disease is not clear. They are most often associated with different dietary habits and lack of physical activity. The recommended treatment and prophylaxis is based on diet and physical intervention at the same time. For early detection of the NWO phenotype, it is recommended to determine the amount of adipose tissue in addition to BMI for the diagnosis of obesity.

Keywords: normal weight obesity, lean obesity, metabolically obese, skinny fat, body fat percentage, health risks.

Received: November 22, 2023; Accepted: April 8, 2024; Published: May 17, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čermáková E, Forejt M. Lean obesity - a hidden health risk. Med. praxi. 2024;21(2):85-87. doi: 10.36290/med.2024.009.
Download citation

References

  1. Dickey RA, Bartuska D, Bray GW, et al. AACE/ACE Position statement on the prevention, diagnosis, and treatment of obesity (1998 revision). Endocr Pr. 1998;4(5):297-350.
  2. Ho­‑Pham LT, Campbell LV, Nguyen TV. More on Body Fat Cutoff Points. Mayo Clin Proc. 2011;86(6):584. Go to original source...
  3. Marques­‑Vidal P, Chiolero A, Paccaud F. Large differences in the prevalence of normal weight obesity using various cut­‑offs for excess body fat. E­‑SPEN Eur E­‑J Clin Nutr Metab. 2008;3(4):e159-62. Go to original source...
  4. Männistö S, Harald K, Kontto J, et al. Dietary and lifestyle characteristics associated with normal­‑weight obesity: the National FINRISK 2007 Study. Br J Nutr. 2014;111(5):887-94. Go to original source... Go to PubMed...
  5. Wijayatunga NN, Dhurandhar EJ. Normal weight obesity and unaddressed cardiometabolic health risk-a narrative review. Int J Obes. 2021;45(10):2141-55. Go to original source... Go to PubMed...
  6. Olafsdottir AS, Torfadottir JE, Arngrimsson SA. Health Behavior and Metabolic Risk Factors Associated with Normal Weight Obesity in Adolescents. PLOS ONE. 2016;11(8):e0161451. Go to original source... Go to PubMed...
  7. Bellissimo MP, Bettermann EL, Tran PH, et al. Physical Fitness but Not Diet Quality Distinguishes Lean and Normal Weight Obese Adults. J Acad Nutr Diet. 2020;120(12):1963-1973.e2. Go to original source... Go to PubMed...
  8. Ferreira FC, Bertucci DR, Barbosa MR, et al. Circuit resistance training in women with normal weight obesity syndrome: body composition, cardiometabolic and echocardiographic parameters, and cardiovascular and skeletal muscle fitness. J Sports Med Phys Fitness. 2017;57(7-8):1033-44. Go to original source... Go to PubMed...
  9. Moy FM, Loh DA. Cardiometabolic risks profile of normal weight obese and multi­‑ethnic women in a developing country. Maturitas. 2015;81(3):389-93. Go to original source... Go to PubMed...
  10. Haghighat N, Ashtary­‑Larky D, Bagheri R, et al. The effect of 12 weeks of euenergetic high­‑protein diet in regulating appetite and body composition of women with normal­‑weight obesity: a randomised controlled trial. Br J Nutr. 2020;124(10):1044-51. Go to original source... Go to PubMed...
  11. Haghighat N, Ashtary­‑Larky D, Bagheri R, et al. Effects of 6 Months of Soy­‑Enriched High Protein Compared to Eucaloric Low Protein Snack Replacement on Appetite, Dietary Intake, and Body Composition in Normal­‑Weight Obese Women: A Randomized Controlled Trial. Nutrients. 2021;13(7):2266. Go to original source... Go to PubMed...
  12. Cota BC, Costa FR, Juvanhol LL, et al. Factors associated with normal­‑weight obesity in adolescents. Br J Nutr. 2023;129(12):2036-45. Go to original source... Go to PubMed...
  13. Lampenius I, Harjutsalo V, Parente EB, et al. Associations between alcohol consumption and body fat distribution in type 1 diabetes. Diabetes Res Clin Pract. 2023;204:110891. Go to original source... Go to PubMed...
  14. Mohammadian Khonsari N, Khashayar P, Shahrestanaki E, et al. Normal Weight Obesity and Cardiometabolic Risk Factors: A Systematic Review and Meta­‑Analysis. Front Endocrinol. 2022;13:857930. Go to original source... Go to PubMed...
  15. Rakhmat II, Putra ICS, Wibowo A, et al. Cardiometabolic risk factors in adults with normal weight obesity: A systematic review and meta­‑analysis. Clin Obes. 2022;12(4):e12523. Go to original source... Go to PubMed...
  16. Mohammadian Khonsari N, Baygi F, et al. Association of normal weight obesity phenotype with inflammatory markers: A systematic review and meta­‑analysis. Front Immunol. 2023;14:1044178. Go to original source... Go to PubMed...
  17. De Lorenzo A, Del Gobbo V, Premrov MG, et al. Normal­‑weight obese syndrome: early inflammation? 2. Am J Clin Nutr. 2007;85(1):40-5. Go to original source... Go to PubMed...
  18. Hauner H. Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc. 2005;64(2):163-9. Go to original source... Go to PubMed...
  19. Romero­‑Corral A, Somers VK, Sierra­‑Johnson J, et al. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J. 2010;31(6):737-46. Go to original source... Go to PubMed...
  20. Xu S, Ming J, Jia A, et al. Normal weight obesity and the risk of diabetes in Chinese people: a 9-year population­‑based cohort study. Sci Rep. 2021;11(1):6090. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.